A5113935019- Tuberculosis Research and Epidemiology
- Pneumonia and Respiratory Infections
- Pharmaceutical studies and practices
- Pneumocystis jirovecii pneumonia detection and treatment
- Health Systems, Economic Evaluations, Quality of Life
- Mycobacterium research and diagnosis
- Drug-Induced Hepatotoxicity and Protection
- Antibiotics Pharmacokinetics and Efficacy
- COVID-19 Clinical Research Studies
- Epilepsy research and treatment
- Health Policy Implementation Science
- Chemical Reactions and Isotopes
- Infectious Diseases and Tuberculosis
- Pharmacological Effects and Toxicity Studies
Kilimanjaro Christian Medical Centre
2021-2025
Christian Medical College & Hospital
2025
Abstract Background New drug classes and regimens have shortened the treatment duration for drug-resistant tuberculosis, but adverse events (AEs) organ toxicity remain unacceptably common. N-acetylcysteine (NAC) has demonstrated potential in reducing kidney liver other clinical settings, efficacy tuberculosis not been rigorously evaluated. Method A randomized controlled trial (PACTR202007736854169) was conducted at Kibong’oto Infectious Disease Hospital Tanzania to assess of NAC AEs patients...
To determine patients' acceptability, satisfaction and adherence to shorter all-oral multidrug-resistant tuberculosis (MDR-TB) regimen in Tanzania. A two-phase cross-sectional study with data collected within 6 months of Removed Injectable modified Short-course regimens for EXpert MDR-TB (RISE) implementation the second phase 15 using same reference populations. 18 health facilities across eight regions Rifampicin-resistant TB/MDR-TB patients enrolled RISE study. We assessed an interval...
Objective: To describe challenges posed by COVID-19 on TB commodity supply, care cascade, active case finding, and responses taken healthcare workers (HCWs) community health (CHWs) during the first year of pandemic (March 2020 to February 2021). Design: A qualitative descriptive study involving 25 in-depth interviews 10 focus group discussions conducted in July 2022. Setting: 37 treatment facilities were purposively selected from seven regions due high notifications 2019 their provision...
Early detection and correction of low fluoroquinolone exposure may improve treatment MDR-TB.
Whole-genome sequencing (WGS)-based prediction of drug resistance in Mycobacterium tuberculosis has the potential to guide clinical decisions design optimal treatment regimens. We utilized WGS investigate mutations a 32-year-old Tanzanian male admitted Kibong'oto Infectious Diseases Hospital with history interrupted multidrug-resistant for more than three years. Before admission, he received various all-oral bedaquiline-based regimens unfavourable outcomes. Drug susceptibility testing serial...
Adverse drug reactions (ADRs) frequently occur in patients using second-line anti-tuberculosis medicine for treatment of multidrug resistant tuberculosis (MDR-TB). ADRs contribute to interruptions which can compromise response and risk acquired resistance critical newer drugs such as bedaquiline, while severe carry considerable morbidity mortality. N-acetylcysteine (NAC) has shown promise reducing medications related TB case series or randomized controlled trials other medical conditions,...
Introduction Tanzania is adapting a shortened injectable-free multidrug resistant tuberculosis (MDR-TB) regimen, comprising new drugs such as bedaquiline and delamanid repurposed clofazimine linezolid. The regimen implemented using pragmatic prospective cohort study within the National TB Leprosy Programme accompanied by process evaluation. evaluation aims to unpack implementation processes, their outcomes moderating factors in order understand clinical effectiveness of regimen. This...
Abstract Background : Adverse drug reactions (ADRs) frequently occur in patients using second-line anti-tuberculosis medicine for treatment of multidrug resistant tuberculosis (MDR-TB). ADRs contribute to interruptions which can compromise response and risk acquired resistance critical newer drugs such as bedaquiline, while severe carry considerable morbidity mortality . N-acetylcysteine (NAC) has shown promise reducing medications related TB case series or randomized controlled trials other...